Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
EU regulators to fast-track Janssen’s multiple myeloma CAR-TEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XEU regulators to fast-track Janssen’s multiple myeloma CAR-Thttps://pharmaphorum.com/news/eu-regulators-to-fast-track-janssens-multiple-myeloma-car-t/
GSK mulls filings for multiple myeloma drugGlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost Share XGSK mulls filings for multiple myeloma drughttps://pharmaphorum.com/news/gsk-mulls-filings-for-multiple-myeloma-drug/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
Advisers urge FDA to delay decision on Karyopharm cancer drugAdvisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination Share XAdvisers urge FDA to delay decision on Karyopharm cancer drughttps://pharmaphorum.com/news/advisers-urge-fda-to-delay-decision-on-karyopharm-cancer-drug/
Sanofi’s Darzalex rival hits the mark in phase 3 trialJohnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition Share XSanofi’s Darzalex rival hits the mark in phase 3 trialhttps://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/
Sanofi gets opt-in rights to two Regeneron cancer drugsSanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights Share XSanofi gets opt-in rights to two Regeneron cancer drugshttps://pharmaphorum.com/news/sanofi-gets-opt-in-rights-to-two-regeneron-cancer-drugs/
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerThe American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance Share XASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerhttps://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/
